It almost never fails: Some bold, new venture with incredible economic potential – nuclear or wind power facilities, a new airport, or, in this latest case, legal weed – is just about set to hang out its shingle (and make a ton of money), when from the neighbors we hear…
"Not in my backyard!"
"NIMBYism." This latest manifestation is happening in Maryland – home of Money Morning and my East Coast base… and a massive potential market for marijuana.
The industry is ready to go, the consumers are ready to buy, and the bureaucrats are ready to okay it. But…
Legal medical marijuana dispensaries in the Old Line State are facing opposition from folks who don't want cannabis sales happening in their neighborhoods.
I've seen this happen before, as it happens, in my backyard in the San Francisco Bay Area.
So let me tell you briefly how it's likely to turn out and what kind of impact this could have on those cannabis-derived gains we've been enjoying lately.
With This Much Profit, They Could Put It in My Backyard
Like I said, my colleagues at Money Morning are based in Baltimore – so they're seeing this latest bout of "NIMBYism" up close.
They read in The Baltimore Sun on Oct. 24, 2017, some residents of Pikesville, a Baltimore inner suburb, gathered in a hearing room to tell a zoning appeals board that allowing a dispensary to operate in their community would make traffic worse and attract "unsavory people."
"Weed Investors' Bible": More than 30 of Michael's favorite pot stock picks. Click here for details…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.